Management of cirrhosis in diabetes: a pragmatic approach to the patient
The Journal of Clinical Endocrinology & Metabolism · 18.11.2026 · 111 (12) · 3599-3610
DOI: 10.1210/clinem/dgag321 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 11.08.2026. Verfasst von Ashish Kumar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Sir Ganga Ram Hospital, New Delhi, India. Die Arbeit nennt 91 Literaturangaben. Gefördert von: National Institute of Diabetes and Digestive and Kidney Diseases.
Themen: Diabetes mellitus
Abstract (Originalsprache)
As the global burden of cirrhosis shifts toward metabolic dysfunction–associated steatotic liver disease (MASLD), diabetes and metabolic syndrome act as key upstream drivers of liver injury. At the same time, diabetes is increasingly recognized even in cirrhosis of nonmetabolic etiologies, including viral hepatitis, reflecting both shared risk factors and cirrhosis-related disturbances in glucose homeostasis. This coexistence amplifies morbidity, mortality, and therapeutic complexity, while conventional diabetes paradigms often prove inadequate in the management of cirrhosis. This review synthesizes current evidence and proposes a pragmatic framework for managing diabetes across the full spectrum of cirrhosis. We examine the evolving concept of hepatogenous diabetes, limitations of HbA1c in advanced liver disease, and the complementary roles of oral glucose tolerance testing and continuous glucose monitoring in improving diagnostic accuracy. The pharmacologic landscape is critically evaluated, integrating contemporary diabetes guidelines with hepatic stage–specific considerations. Metformin remains the backbone of therapy in compensated cirrhosis. Among newer agents, glucagon-like peptide-1 receptor agonists and sodium–glucose co-transporter-2 inhibitors show promise in compensated disease, particularly in patients with MASLD and cardiorenal comorbidities. In contrast, sulfonylureas, insulin secretagogues, and agents associated with fluid retention require caution or avoidance as hepatic reserve declines. Insulin therapy remains the cornerstone in decompensated cirrhosis and during hospitalization, where conservative dosing and dynamic titration are essential to minimize hypoglycemia. The review emphasizes nutritional optimization, frequent reassessment, and coordinated hepatology–endocrinology care. As diabetes in cirrhosis increasingly reflects the convergence of 2 metabolic disorders, management must prioritize hepatic safety, metabolic stability, and individualized outcomes over rigid glycemic targets.
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Sir Ganga Ram Hospital, New Delhi, India.
- Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
ORCID-Profile: Rita Basu
Förderung
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Kumar, A., & Basu, R. (2026). Management of cirrhosis in diabetes: a pragmatic approach to the patient. The Journal of Clinical Endocrinology & Metabolism, 111(12), 3599-3610. https://doi.org/10.1210/clinem/dgag321
Vancouver
Kumar A, Basu R. Management of cirrhosis in diabetes: a pragmatic approach to the patient. The Journal of Clinical Endocrinology & Metabolism. 2026;111(12):3599-3610. doi:10.1210/clinem/dgag321
BibTeX
@article{Kumar2026,
author = {Kumar, Ashish and Basu, Rita},
title = {Management of cirrhosis in diabetes: a pragmatic approach to the patient},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {12},
pages = {3599--3610},
doi = {10.1210/clinem/dgag321}
}
EUVIMED